Abbott Laboratories stock forecast for 2030: Exact Sciences acquisition reshapes growth outlook toward $180

Traders Union
All News
Financial News
ABT Exact Sciences Acquisition

Highlights

Abbott trades at $116.35, down 18% from $141 highs after Q4 revenue miss and FreeStyle Libre Class I recall.
Stock could reach $150-190 by 2030 if Exact Sciences adds high-teens growth and medical devices sustain 12 straight double-digit quarters.
ABT prices $20B debt for $21B Exact Sciences deal, posts 10.4% medical devices growth, but faces Class I recall with 860 injuries and 7 deaths.

The closing is anticipated on March 9, 2026. This debt will support Abbott's $21 billion all-cash acquisition of Exact Sciences, which is set to finalize in the second quarter of 2026 after shareholders approved the deal on February 20.

Abbott plans to buy all outstanding shares of Exact Sciences for $105 per share in cash, bringing the total equity value to around $21 billion and an estimated enterprise value of $23 billion. Exact Sciences is expected to generate over $3 billion in revenue this year, with a strong organic sales growth rate in the high teens. Once the acquisition is complete, Exact Sciences will operate as a subsidiary of Abbott, and Abbott's total diagnostics sales will surpass $12 billion annually.

Abbott stock price update

Abbott stock is trying to recover from a big drop that brought the stock down 18% from its high of $141.23. The chart shows that prices were very volatile in 2025 and early 2026, with prices moving between $106 and $138.

ABT price action (Source: TradingView)

The Supertrend at $109.96 is lower than the current price, which gives it support. The overall trend is still under pressure, with a downward trendline stopping any gains near $133–135. The $112–115 zone is where immediate support is, and the $109.96 level is where stronger support is. There is resistance at $118–120 and then again at $125–128. To change the momentum, there would need to be a sustained break above $120.

Medical devices posts 12th straight double-digit growth quarter

Full-year 2025 sales totaled $44.3 billion, a 6.7% organic increase. Fourth-quarter adjusted diluted EPS grew 12% to $1.50. Revenue reached $11.46 billion in Q4, missing the projected $11.8 billion. Medical device sales grew 10.4% on an organic basis in Q4, marking the 12th consecutive quarter of double-digit growth. Adjusted gross margin was 57.1%, and adjusted operating margin was 25.8%, reflecting 150 basis points of expansion.

Abbott's sales of continuous glucose monitors (CGMs) surpassed $7.5 billion for the entire year, with a 12% growth in the fourth quarter and a total annual growth of 17%. In the field of electrophysiology, Abbott received the CE Mark for its new TactiFlex Duo ablation catheter. The structural heart segment saw significant growth, fueled by double-digit increases in the Navitor, TriClip, and MitraClip products. Additionally, on February 27, the FDA granted approval for Abbott's CardioMEMS HF System, designed for individuals living with heart failure.

FreeStyle Libre recall logs 860 injuries and 7 deaths

As of January 7, 2026, Abbott has reported 860 serious injuries and seven fatalities linked to a manufacturing defect in certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors. The FDA has classified this issue as a Class I Recall, which signifies a significant risk of serious health consequences or even death. The problem arises from sensors providing glucose readings that are lower than the actual blood glucose levels of users. Around 3 million sensors have been impacted.

Abbott also received a warning letter from the FDA dated January 23 related to an inspection at its diabetes care site in Alameda, California. A class action lawsuit has been filed in California federal court, alleging Abbott knowingly sold defective sensors.

Abbott guided to 2026 full-year organic sales growth of 6.5% to 7.5% and adjusted EPS of $5.55 to $5.80. The midpoint reflects approximately 10% growth. Abbott declared a quarterly common dividend of $0.63 per share, extending its Dividend Aristocrat status with a 6.8% increase, marking the 54th consecutive annual increase.

Recently, Abbott declined from $141 to $116 after Q4 revenue missed estimates and the FreeStyle Libre Class I recall revealed 860 injuries and 7 deaths. The stock tested support near $112-115 as investors weighed whether the $21 billion Exact Sciences bet and 12 straight quarters of double-digit medical device growth justify the valuation amid recall fallout.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.